Press Page

All Press Releases

July 10, 2008 NLA Statement on New Cholesterol Guidelines for Children January 16, 2008: NLA Statement on ENHANCE Study Findings: Premature Judgment Unwarranted June 14, 2007: Reach MD and National Lipid Association Partner to Offer First-Ever Radio Show Focused on Heart Disease and Lipids Beginning June 25 March 24, 2007: NLA Safety Task Force Releases Findings on Non-Statin Lipid-Lowering Therapies September 22, 2006: National Survey Shows Patients Are Unaware of Serious Heart Risks of Triglycerides April 7, 2006: National Lipid Association Statin Study: Required Liver Monitoring Unnecessary May Be Causing Patients to Forego Life-Saving Cholesterol Treatment

FOR IMMEDIATE RELEASE
JANUARY 16, 2008

CONTACT:
Daniel Sosnoski
Director of Communications
National Lipid Association
904-998-0854
dsosnoski@lipid.org

NLA Statement on ENHANCE Study Findings: Premature Judgment Unwarranted

The limitations of the ENHANCE study, in terms of its design and the patients studied, are such that physicians should not alter their prescribing policies at this time. Current discussion regarding the ENHANCE Study is not based upon published work subject to peer review and thus cannot yet be evaluated by the medical community.

The ENHANCE trial was not powered to examine differences in clinical outcomes. The limitations in question include the patient population studied, which were patients who had familial hypercholesterolemia with an average baseline LDL-C of 319 mg/dL. The statin-ezetimibe combination reduced LDL-C more than did the statin alone. However, there were no statistically significant differences in the primary endpoint, which was carotid intimal-media thickness, as measured by ultrasound. The combination therapy (Vytorin) resulted in a greater reduction of LDL-C (17 percent) compared to simvastatin alone. Further, the therapy examined does not present safety concerns as there were no differences in adverse events between the two treatment groups.

Given that other studies are currently in progress to examine cardiovascular endpoints, generalization and extrapolation of ENHANCE results to different populations with regard to clinical outcomes is premature.

The National Cholesterol Education Program (NCEP) guidelines suggest patient goals but do not specify which drugs should be used to attain them. That matter is left to the judgment of the physician, whose primary objective is to help patients reach their treatment targets.

The NLA re-emphasizes the importance of following NCEP guidelines and ezetimibe and its combination form remain reasonable options that can be safely prescribed when appropriate. Until the ENHANCE Study is formally published and presented to the medical community, there is no basis on which physicians can make an informed decision and to do so now would be an unwarranted rush to judgment.

###

ABOUT THE NATIONAL LIPID ASSOCIATION
The National Lipid Association (NLA) is a multidisciplinary non-profit membership association that serves the community of healthcare professionals who manage patients with lipid disorders and cardiovascular disease. The NLA's public health mission is to help reduce deaths related to high cholesterol. For more information, please see the NLA Web site at: www.lipid.org.